Fluidigm Corporation — Q1 2017 Form 10-Q
Filing identity: The provided filing is for Fluidigm Corporation, for the three months ended March 31, 2017. It does not identify Standard BioTools Inc. as the registrant; verify that this is the intended filing.
Business context and reporting period
Fluidigm develops, manufactures, and sells life-sciences research tools, instruments, consumables, assays, and services for genomics and mass cytometry applications. The unaudited results below compare Q1 2017 with Q1 2016; balance-sheet figures compare March 31, 2017 with December 31, 2016.
Financial performance and liquidity
| Metric | Q1 2017 / March 31, 2017 | Prior comparable period |
|---|---|---|
| Total revenue | $25.5 million | $29.0 million; down 12% |
| Product revenue | $21.3 million | $25.4 million; down 16% |
| Service revenue | $4.2 million | $3.5 million; up 18% |
| Operating loss | $17.5 million | $18.9 million |
| Net loss | $17.2 million; $0.59 per share | $19.9 million; $0.69 per share |
| Operating cash flow | $(8.5) million | $(7.8) million |
| Cash and short-term investments | $50.3 million | $59.4 million at Dec. 31, 2016 |
| Total assets | $292.5 million | $306.4 million at Dec. 31, 2016 |
| Convertible notes | $201.3 million principal; $195.0 million net carrying value | $195.0 million net carrying value |
Product margin fell to 49% from 57%; management attributed the decline to lower production volumes, fixed technology amortization against lower sales, lower prices, and an unfavorable instrument mix. Service margin improved to 73% from 66%. Total current liabilities were $31.3 million; working capital excluding deferred revenue was $64.7 million. The company reported an accumulated deficit of $456.9 million.
Material changes, outlook, risks, and contingencies
- Revenue declines were concentrated in instruments and genomics consumables: instrument revenue fell 22% and consumables fell 9%. Management cited weaker genomics instrument demand, including single-cell genomics, and performance issues in certain C1 integrated fluidic circuits; growth in imaging mass cytometry partly offset declines.
- R&D expense declined 18% to $8.5 million and selling, general and administrative expense declined 11% to $22.6 million. The company began workforce reductions and facility and cost-efficiency actions in Q1, and expected both expense categories to decrease in 2017. It cautioned that cuts or deferred investment could impair product development, marketing, and sales.
- Cash increased during the quarter primarily because $19.4 million of investments matured or were sold; this more than offset $8.5 million of operating cash use. Capital expenditures were $0.7 million. Management said existing cash and investments were expected to fund working-capital and capital needs for at least 18 months, but noted that weaker cash generation or higher costs could require additional financing.
- The $201.3 million principal amount of 2.75% senior convertible notes is due in 2034. Holders have specified repurchase rights beginning in 2021 and on a fundamental change; the notes are convertible, and conversion may dilute shareholders.
- Thermo Fisher Scientific litigation names Fluidigm and a former Thermo employee and seeks damages and injunctive relief. The company said the case was at an early stage and the ultimate outcome and potential loss could not be estimated; its aggregate legal contingency accrual was not material at quarter-end.
- Key stated risks include continued revenue declines and losses, competition and pricing pressure, product and manufacturing defects, reliance on single- or sole-source suppliers and concentrated manufacturing sites, international and currency exposure, potential impairment of goodwill or intangible assets, and the possibility that cost reductions or future financing needs affect operations. Management reported disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Confirm the intended registrant: the filing names Fluidigm Corporation, not Standard BioTools Inc.
- Track subsequent revenue and instrument demand, especially single-cell genomics, C1 product performance, and imaging mass cytometry uptake.
- Assess whether expense reductions improve cash burn without undermining research, product development, and commercial capabilities.
- Review liquidity against operating cash use, the stated 18-month funding estimate, and the notes’ repurchase and conversion terms.
- Monitor the Thermo Fisher litigation and any developments affecting the company’s significant goodwill and intangible-asset balances.